Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Livermore

Showing results (81-90 of 269) with videos related to

Pageof 27
Sort By:
The Journal of Antimicrobial Chemotherapy|October 10, 2008
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06Russell Hope, David M Livermore, Geraldine Brick, et al.
Antimicrobial Agents and Chemotherapy|January 11, 2007
In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococciDavid M Livermore, Marina Warner, Shazad Mushtaq, et al.
International Journal of Antimicrobial Agents|March 15, 2021
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteriaShazad Mushtaq, Paolo Garello, Anna Vickers, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2017
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteriaDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Lancet. Infectious Diseases|April 12, 2011
Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence studyTimothy R Walsh, Janis Weeks, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2012
Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UKVassiliki Dimou, Hiran Dhanji, Rachel Pike, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2019
Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' responseAlicia H Russell, Carolyne Horner, David M Livermore, et al.
Journal of Chemotherapy (Florence, Italy)|July 5, 2012
Antimicrobial resistance among Gram-positive pathogens in Saudi ArabiaSaber Yezli, Atef M Shibl, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|September 27, 2021
Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing EnterobacteralesShazad Mushtaq, Anna Vickers, Nicholas Ellaby, et al.
The Journal of Antimicrobial Chemotherapy|August 6, 2010
Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpointsRussell Hope, Teresa Pllana, Dorothy James, et al.
Pageof 27

Showing results (81-90 of 269) with videos related to

Sort By:
Pageof 27
The Journal of Antimicrobial Chemotherapy|October 10, 2008
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06Russell Hope, David M Livermore, Geraldine Brick, et al.
Antimicrobial Agents and Chemotherapy|January 11, 2007
In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococciDavid M Livermore, Marina Warner, Shazad Mushtaq, et al.
International Journal of Antimicrobial Agents|March 15, 2021
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteriaShazad Mushtaq, Paolo Garello, Anna Vickers, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2017
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteriaDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Lancet. Infectious Diseases|April 12, 2011
Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence studyTimothy R Walsh, Janis Weeks, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2012
Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UKVassiliki Dimou, Hiran Dhanji, Rachel Pike, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2019
Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' responseAlicia H Russell, Carolyne Horner, David M Livermore, et al.
Journal of Chemotherapy (Florence, Italy)|July 5, 2012
Antimicrobial resistance among Gram-positive pathogens in Saudi ArabiaSaber Yezli, Atef M Shibl, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|September 27, 2021
Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing EnterobacteralesShazad Mushtaq, Anna Vickers, Nicholas Ellaby, et al.
The Journal of Antimicrobial Chemotherapy|August 6, 2010
Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpointsRussell Hope, Teresa Pllana, Dorothy James, et al.
Pageof 27